We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
John Heiss MD

John D. Heiss MD

Head, Clinical Unit, Surgical Neurology Branch, NINDS, National Institutes of Health, Bethesda, Maryland

John D. Heiss, MD, is the Head of the Clinical Unit of the Surgical Neurology Branch and Program Director of the Neurological Surgery Residency Training Program in the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) in Bethesda, Maryland. He is actively involved in clinical and translational research to improve the understanding and treatment of Chiari I malformation, syringomyelia, pain, brain tumors, and Parkinson’s disease. He is board certified in neurological surgery and is expert in the supervision and conduct of clinical trials for CNS disorders. Dr. Heiss received both his B.S. in Biomedical Sciences and his M.D. degree from the University of Michigan. He completed his surgical internship and his residency in neurosurgery at the University of Cincinnati College of Medicine. Prior to joining NINDS, Dr. Heiss was co-director of the Neuroscience Intensive Care Unit at the University of Cincinnati.


Neither Dr. Heiss nor his institution received payment or services from a third party for any aspect of the submitted work.
Dr. Heiss:
  • Has no relevant financial activities outside the submitted work;
  • Has no patents, whether planned, pending or issued, broadly relevant to the work;
  • Has no relationships or activities that would give the appearance of potentially influencing what he wrote in the submitted article.

Dr. Heiss is the Principal Investigator of two Phase I Clinical Trials: 1) Resiniferatoxin to Treat Sever Pain Associated with Advance Cancer and 2) Periganglionic Resiniferatoxin for the Treatment of Intractable Pain due to Cancer-induced Bone Pain (further information available at https://www.clinicaltrials.gov).  He made no mention of the experimental use of resiniferatoxin in his PracticeUpdate review of the article on guidelines for neuroablative procedures for cancer pain.